Instead of PD-L1 testing by immunohistochemistry, which has been approved by the FDA as an acceptable biomarker for several cancers, a lack of standard methods for evaluating PD-L1 expression and its spatial and temporal heterogeneity still limits its use in addressing HCC [82]. The gene discussed is CD274; the disease is cancer.